ERBB2 and hypothyroidism: This interpretation is supported by preclinical data implicating HER2-dependent signaling in trastuzumab-associated lipid effects (25), and by clinical reports linking pembrolizumab-induced hypothyroidism to impaired lipid clearance and subsequent elevations in LDL-C and TG (26, 27).